Dr. Katja Weisel on Cilta-Cell Versus Belantamab Mafodotin 

What is the background of the study?

Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) is a chimeric antigen receptor (CAR) T-cell therapy with two BCMA–targeting, single-domain antibodies designed to confer avidity. In the phase 1b/2 CARTITUDE-1 single arm study (NCT03548207), a single infusion of cilta-cel yielded early, deep, and durable responses with a manageable safety profile in heavily pretreated triple-class exposed (to immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies) RRMM patients. In the absence of head-to-head trials, matched adjusted comparison methods may be helpful to compare the relative efficacy of different treatment regimens. A systematic literature review using PRISMA guidelines identified belantamab mafodotin as a potential BCMA-targeting non-CAR T-cell comparator in the triple-class exposed relapsed/refractory multiple myeloma (RRMM) patient population.

In this video:

Dr. Katja Weisel (Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany) discusses the ciltacabtagene autoleucel versus belantamab mafodotin in relapsed refractory multiple myeloma patients treated with 3 or more lines of prior therapy.

Conclusions:

These analyses demonstrated improved efficacy with cilta-cel versus belantamab mafodotin for overall response rate, ≥ complete response, progression-free survival, and overall survival, highlighting its potential in patients with triple-class exposed RRMM.